#United States #Raleigh #oncology #Accord BioPharma #FILKRI

Accord BioPharma Launches FILKRI™

Accord BioPharma, a division of Intas Pharmaceuticals, has made a significant advancement in oncology supportive care with the recent launch of FILKRI™ (filgrastim-laha), a new biosimilar to Neupogen® (filgrastim). This product, which received FDA approval in January 2026, is aimed at improving the quality of care for patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy.

The introduction of FILKRI™ marks a critical addition to Accord's portfolio, which aims to bring 20 biosimilars to the U.S. market by 2030. The drug is specifically designed to reduce the risk of febrile neutropenia, a potentially dangerous condition caused by low levels of neutrophils, which are essential in fighting infections. By decreasing the incidence of febrile neutropenia and promoting quicker neutrophil recovery, FILKRI aims to enhance patients’ overall treatment experience and outcomes.

Comprehensive Treatment Options

Patients receiving chemotherapy often experience adverse effects that can complicate their treatment protocols. FILKRI™ is available in two prefilled syringe presentations: 300 mcg/0.5 mL and 480 mcg/0.8 mL. By offering both short- and long-acting G-CSF options, such as FILKRI™ and UDENYCA® (pegfilgrastim-cbqv), Accord BioPharma aims to meet the varied needs of patients and healthcare providers. This ensures that doctors can customize their treatment approaches based on individual patient conditions and preferences.

Chrys Kokino, President of Accord North America, remarks, “The commercial launch of FILKRI with a permanent Q-code from day one is a significant milestone for Accord BioPharma and for cancer patients across the United States. Having a permanent Q-code will simplify billing and streamline reimbursement, making it more timely and reliable for physicians treating patients.” This code standardizes billing practices across various care sites, facilitating easier access for patients in need of these essential treatments.

Addressing Neutropenia Management

Neutropenia is an unfortunate consequence of many cancer treatments, and it poses severe risks to patients. The launch of FILKRI is timely, as it comes with essential patient resources through the AccordCares® program, which offers benefits investigations, co-pay assistance, and critical educational materials to patients and their families. Nuvan Dassanaike, Senior Vice President of Digital and Marketing Strategy Operations at Accord, underscores the company’s commitment: “At Accord, we believe that cost shouldn’t prevent patients from receiving the cancer care they need.”

This proactive approach not only aims to improve patient outcomes but also addresses the financial burdens often associated with cancer treatment. The comprehensive support provided by AccordCares® ensures that patients can navigate their treatment journeys more effectively and with less stress.

A Commitment to Oncology Supportive Care

The introduction of FILKRI reflects Accord BioPharma's long-term strategy of developing a robust oncology supportive care portfolio. Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, states, “With the support of Intas, an established global leader with nearly five decades of experience, Accord BioPharma is transforming the conventional treatment landscape by introducing biosimilars to the U.S. market.” This commitment is exemplified by Accord’s aspiration to expand therapy access while maintaining high-quality standards.

As biosimilars continue to gain footing in the U.S. market, the introduction of FILKRI is set to enhance treatment options significantly. Preliminary data show that filgrastim biosimilars have already captured approximately 77% of the market share, highlighting the growing acceptance and demand for these affordable alternatives. Accord’s strategy to increase high-quality biosimilars signifies a pivotal shift in patient care for those undergoing critical treatments.

Conclusion

In summary, the launch of FILKRI™ is a considerable step forward in the realm of oncology supportive care. Accord BioPharma is committed to not only enhancing treatment options for patients but also ensuring that these options are accessible and affordable. With its innovative approach and comprehensive patient support systems, Accord is poised to make a lasting impact in improving patient outcomes in cancer care. As the company advances towards its goal of launching 20 biosimilars by 2030, FILKRI is emblematic of its dedication to creating meaningful change in the healthcare landscape.